These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 29307569)

  • 1. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
    Nussinov R; Tsai CJ; Jang H
    Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
    Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
    Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
    Nussinov R; Tsai CJ; Jang H
    Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic KRas mobility in the membrane and signaling response.
    Nussinov R; Tsai CJ; Jang H
    Semin Cancer Biol; 2019 Feb; 54():109-113. PubMed ID: 29499269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
    Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
    Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Mystery of Rap1 Suppression of Oncogenic Ras.
    Nussinov R; Jang H; Zhang M; Tsai CJ; Sablina AA
    Trends Cancer; 2020 May; 6(5):369-379. PubMed ID: 32249186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.
    Spencer-Smith R; Li L; Prasad S; Koide A; Koide S; O'Bryan JP
    Small GTPases; 2019 Sep; 10(5):378-387. PubMed ID: 28692342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.
    Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R
    J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calmodulin and PI3K Signaling in
    Nussinov R; Wang G; Tsai CJ; Jang H; Lu S; Banerjee A; Zhang J; Gaponenko V
    Trends Cancer; 2017 Mar; 3(3):214-224. PubMed ID: 28462395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
    Terrell EM; Durrant DE; Ritt DA; Sealover NE; Sheffels E; Spencer-Smith R; Esposito D; Zhou Y; Hancock JF; Kortum RL; Morrison DK
    Mol Cell; 2019 Dec; 76(6):872-884.e5. PubMed ID: 31606273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution and characterization of BRAF in complex with 14-3-3 and KRAS4B on nanodiscs.
    Liu NF; Enomoto M; Marshall CB; Ikura M
    Protein Sci; 2024 Jun; 33(6):e5016. PubMed ID: 38747381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling.
    Muratcioglu S; Aydin C; Odabasi E; Ozdemir ES; Firat-Karalar EN; Jang H; Tsai CJ; Nussinov R; Kavakli IH; Gursoy A; Keskin O
    J Mol Biol; 2020 Feb; 432(4):1199-1215. PubMed ID: 31931009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling.
    Villalonga P; López-Alcalá C; Bosch M; Chiloeches A; Rocamora N; Gil J; Marais R; Marshall CJ; Bachs O; Agell N
    Mol Cell Biol; 2001 Nov; 21(21):7345-54. PubMed ID: 11585916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers.
    Najumudeen AK; Posada IM; Lectez B; Zhou Y; Landor SK; Fallarero A; Vuorela P; Hancock J; Abankwa D
    Biochemistry; 2015 Dec; 54(49):7212-21. PubMed ID: 26568031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
    Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
    PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type NRas and KRas perform distinct functions during transformation.
    Fotiadou PP; Takahashi C; Rajabi HN; Ewen ME
    Mol Cell Biol; 2007 Oct; 27(19):6742-55. PubMed ID: 17636015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.